CONSHOHOCKEN, PA — Cencora, Inc. (NYSE: COR) posted higher revenue and profits in its fiscal third quarter, driven by growth in both U.S. and international healthcare operations, and raised its full-year earnings guidance.
Revenue for the quarter ended June 30 rose 8.7% year-over-year to $80.7 billion, fueled by an 8.5% increase in U.S. Healthcare Solutions sales and a 10.5% gain in International Healthcare Solutions. GAAP diluted earnings per share climbed 45.5% to $3.52, while adjusted diluted EPS grew 19.8% to $4.00.
Gross profit jumped 20.6% to $2.9 billion, boosted by higher margins in the U.S. segment following the January acquisition of Retina Consultants of America and a favorable LIFO credit. Operating income rose 29% to $900 million, despite a 17.3% rise in operating expenses tied to the RCA acquisition and business expansion.
U.S. Healthcare Solutions generated $72.9 billion in revenue, with operating income up 29.1% on stronger demand for GLP-1 diabetes and weight-loss therapies and specialty medicines. International Healthcare Solutions revenue grew to $7.8 billion, though operating income fell 12.9% due to weaker results in global specialty logistics and consulting services.
Cencora lifted its fiscal 2025 adjusted EPS guidance to $15.85–$16.00 from $15.70–$15.95, citing stronger U.S. segment performance. The company now expects overall revenue growth of about 9% and adjusted operating income growth of 15–16%. U.S. operating income is projected to rise 20–21%, while international segment income is forecast to fall around 6%.
President and CEO Robert P. Mauch credited the results to the company’s pharmaceutical-centric strategy, investments in growth initiatives, and productivity gains.
The board declared a quarterly dividend of $0.55 per share, payable September 3 to shareholders of record as of August 15.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.